Free Trial

Adaptive Biotechnologies Q2 2024 Earnings Report

Adaptive Biotechnologies logo
$7.45 -0.22 (-2.87%)
As of 12:44 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Adaptive Biotechnologies EPS Results

Actual EPS
-$0.31
Consensus EPS
-$0.33
Beat/Miss
Beat by +$0.02
One Year Ago EPS
-$0.33

Adaptive Biotechnologies Revenue Results

Actual Revenue
$43.19 million
Expected Revenue
$38.63 million
Beat/Miss
Beat by +$4.56 million
YoY Revenue Growth
-11.70%

Adaptive Biotechnologies Announcement Details

Quarter
Q2 2024
Time
After Market Closes

Conference Call Resources

Remove Ads

Adaptive Biotechnologies Earnings Headlines

7 Stocks Set to Win Big Under Trump’s America First Agenda 🚀
The Trump economy is back in full force, and it’s creating huge opportunities for investors. With Trump pushing for lower taxes, fewer regulations, tariffs on foreign competitors, and domestic manufacturing dominance, some stocks are set to skyrocket in value—while others will be left behind. That’s why we put together this free report revealing the 7 MAGA stocks poised to thrive in 2025.
See More Adaptive Biotechnologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Adaptive Biotechnologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adaptive Biotechnologies and other key companies, straight to your email.

About Adaptive Biotechnologies

Adaptive Biotechnologies (NASDAQ:ADPT), a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

View Adaptive Biotechnologies Profile

More Earnings Resources from MarketBeat